Press Release: “Hunting the Nightmare Bacteria”

FRONTLINE INVESTIGATES THE RISE OF DEADLY, DRUG-RESISTANT BACTERIA THAT MODERN ANTIBIOTICS CAN’T STOP

FRONTLINE Presents
Hunting the Nightmare Bacteria
Tuesday, October 22, 2013, at 10 p.m. on PBS
www.facebook.com/frontline | Twitter: @frontlinepbs #frontlinepbs
[2]
https://www.pbs.org/frontline[1][3]

Addie Rerecich was a happy 11-year-old girl who loved sports and talked a mile a minute. But when a mysterious pain in her hip landed her in the hospital in 2011, she began a downward spiral into the nightmare of a new kind of antibiotic-resistant infection that is confounding doctors across the world.

Addie’s precipitous decline might sound unusual, but as FRONTLINE reports in Hunting the Nightmare Bacteria, premiering Tuesday, Oct. 22, at 10 p.m. (check local PBS listings[4]), medicine’s struggle with deadly drug-resistant infections is becoming all too real.

“The world is entering a post-antibiotic era. Doctors tell me there are patients for whom we have no therapy. The bacteria are growing stronger, and the drug pipeline is drying up,” says award-winning journalist David E. Hoffman, who investigates the crisis for FRONTLINE.

In Hunting the Nightmare Bacteria, Hoffman examines the alarming rise of superbugs that our modern antibiotics can’t stop—from Addie Rerecich’s case to that of David Ricci, who brings a nasty infection home from India, and to a rare look inside an uncontrollable outbreak at the National Institutes of Health Clinical Center—the NIH—one of the nation’s most prestigious research hospitals, where 19 patients were sickened and seven died.

“The rise of antimicrobial resistance is a threat to us all. Prominent public health officials are using words like ‘nightmare’ and ‘catastrophic,’” Hoffman says. “But even though we’ve known about this problem for decades, the alarms have not been met with similar levels of urgency in the public or the government.”

As FRONTLINE reports, after decades of antibiotic overuse, the crisis of untreatable infections has only deepened. Most major drug companies, squeezed by Wall Street expectations and facing steep scientific hurdles, have abandoned the development of new antibiotics. The film takes viewers behind the story of one major drug company’s efforts to overcome the new drug-resistant superbugs—and why, despite those efforts, the drug pipeline is running dry.

“Twenty-five years ago, there were more than 25 large companies working to discover and develop new antibiotics,” infectious disease doctor Brad Spellberg tells FRONTLINE. “Now there’s two, maybe three.”

Compounding the problem is the fact that these superbugs are now spreading in frightening ways with alarming speed, both across the globe and inside hospitals—though few hospitals are willing to talk about the problem publicly.

But FRONTLINE was granted unprecedented access to the NIH, where some of the nation’s top clinical specialists struggled to control the spread of a deadly outbreak in 2011. The specialists remain confounded—and their experience has serious implications for the rest of the country: These new threats have been found in almost every state.

“The average person thinks, ‘Oh, I have an infection, I take an antibiotic, I get better,’” says nurse Tonya Rerecich, whose daughter Addie’s story is featured in the FRONTLINE report. “Yeah, it’s not that simple anymore.”

Credits

Hunting the Nightmare Bacteria is a FRONTLINE production with American University School of Communication’s Investigative Reporting Workshop.

The director and producer is Rick Young. The co-producer and editor is Anthony Szulc. The correspondent is David E. Hoffman. The deputy executive producer of FRONTLINE is Raney Aronson-Rath. The executive producer of FRONTLINE is David Fanning.

About FRONTLINE

FRONTLINE, U.S. television’s longest running investigative documentary series, explores the issues of our times through powerful storytelling. The series has won every major journalism and broadcasting award, including 65 Emmy Awards and 14 Peabody Awards. More than 150 FRONTLINE films can be watched online at pbs.org/frontline[5].

FRONTLINE is produced by WGBH Boston and is broadcast nationwide on PBS. Funding for FRONTLINE is provided through the support of PBS viewers and by the Corporation for Public Broadcasting. Major funding for FRONTLINE is provided by The John D. and Catherine T. MacArthur Foundation. Additional funding is provided by the Park Foundation, the Wyncote Foundation and the FRONTLINE Journalism Fund. Major funding for Hunting the Nightmare Bacteria is provided by The Kendeda Fund. FRONTLINE is closed-captioned for deaf and hard-of-hearing viewers by the Media Access Group at WGBH. FRONTLINE is a registered trademark of the WGBH Educational Foundation.

Press Contacts:

Diane Hebert-Farrell, (617) 300-5366, diane_hebert_farrell@wgbh.org
Patrice Taddonio, (617) 300-5375, patrice_taddonio@wgbh.org
[6][7]

pbs.org/pressroom: Download promotional photography from the PBS Pressroom.

Source URL: Read More
The public content above was dynamically discovered – by graded relevancy to this site’s keyword domain name. Such discovery was by systematic attempts to filter for “Creative Commons“ re-use licensing and/or by Press Release distributions. “Source URL” states the content’s owner and/or publisher. When possible, this site references the content above to generate its value-add, the dynamic sentimental analysis below, which allows us to research global sentiments across a multitude of topics related to this site’s specific keyword domain name. Additionally, when possible, this site references the content above to provide on-demand (multilingual) translations and/or to power its “Read Article to Me” feature, which reads the content aloud to visitors. Where applicable, this site also auto-generates a “References” section, which appends the content above by listing all mentioned links. Views expressed in the content above are solely those of the author(s). We do not endorse, offer to sell, promote, recommend, or, otherwise, make any statement about the content above. We reference the content above for your “reading” entertainment purposes only. Review “DMCA & Terms”, at the bottom of this site, for terms of your access and use as well as for applicable DMCA take-down request.

Acquire this Domain
You can acquire this site’s domain name! We have nurtured its online marketing value by systematically curating this site by the domain’s relevant keywords. Explore our content network – you can advertise on each or rent vs. buy the domain. Buy@TLDtraders.com | Skype: TLDtraders | +1 (475) BUY-NAME (289 – 6263). Thousands search by this site’s exact keyword domain name! Most are sent here because search engines often love the keyword. This domain can be your 24/7 lead generator! If you own it, you could capture a large amount of online traffic for your niche. Stop wasting money on ads. Instead, buy this domain to gain a long-term marketing asset. If you can’t afford to buy then you can rent the domain.

About Us
We are Internet Investors, Developers, and Franchisers – operating a content network of several thousand sites while federating 100+ eCommerce and SaaS startups. With our proprietary “inverted incubation” model, we leverage a portfolio of $100M in valued domains to impact online trends, traffic, and transactions. We use robotic process automation, machine learning, and other proprietary approaches to power our content network. Contact us to learn how we can help you with your online marketing and/or site maintenance.

Share